Immunovant, Inc.

General ticker "IMVT" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $3.8B (TTM average)

Immunovant, Inc. follows the US Stock Market performance with the rate: 13.4%.

Estimated limits based on current volatility of 3.2%: low 14.43$, high 15.39$

Factors to consider:

  • Price in estimated range
  • Earnings for 9 months up through Q3 are below our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2024-03-31 to 2026-03-31

  • 2024-03-31 to 2025-03-31 estimated range: [16.01$, 39.37$]
  • 2025-03-31 to 2026-03-31 estimated range: [10.15$, 26.79$]

Financial Metrics affecting the IMVT estimates:

  • Negative: Non-GAAP EPS, $ of -1.80 <= 0.04
  • Negative: Operating cash flow per share per price, % of -4.48 <= 1.79
  • Negative: negative Net income
  • Positive: Inventory ratio change, % of -0.06 <= 0
  • Negative: negative Operating income
  • Negative: Industry operating cash flow per share per price (median), % of -25.87 <= 2.82
  • Positive: Interest expense per share, $ of 0 <= 0
  • Negative: negative Industry operating income (median)
  • Negative: -0.28 < Industry inventory ratio change (median), % of 0

Similar symbols

Short-term IMVT quotes

2025-03-122025-03-132025-03-142025-03-172025-03-182025-03-192025-03-202025-03-212025-03-242025-03-252025-03-262025-03-272025-03-282025-03-312025-04-012025-04-022025-04-032025-04-042025-04-072025-04-082025-04-092025-04-102025-04-112025-04-142025-04-152025-04-162025-04-172025-04-212025-04-222025-04-231314151617181920
Price $

Long-term IMVT plot with estimates

1015202530354045Jul 2023Jan 2024Jul 2024Jan 2025Jul 2025Jan 2026−0.8−0.6−0.4−0.20
IMVTS&P500Health CareNon-GAAP EPS EstimateNon-GAAP EPS ActualPrice $Non-GAAP EPS $

Financial data

YTD 2022-03-31 2023-03-31 2024-03-31
Operating Revenue $0.00MM $0.00MM $0.00MM
Operating Expenses $156.81MM $198.47MM $282.71MM
Operating Income $-156.81MM $-198.47MM $-282.71MM
Non-Operating Income $0.00MM $-12.48MM $23.94MM
Interest Expense $0.00MM $12.48MM $0.00MM
R&D Expense $101.81MM $160.26MM $225.43MM
Income(Loss) $-156.81MM $-210.95MM $-258.77MM
Taxes $-0.08MM $0.01MM $0.57MM
Profit(Loss)* $-156.73MM $-210.96MM $-259.34MM
Stockholders Equity $469.82MM $362.49MM $617.76MM
Inventory $0.00MM $0.00MM $0.00MM
Assets $515.56MM $405.84MM $666.37MM
Operating Cash Flow $-106.11MM $-188.19MM $-214.23MM
Capital expenditure $0.25MM $0.20MM $0.36MM
Investing Cash Flow $-0.25MM $-0.20MM $-0.36MM
Financing Cash Flow $200.13MM $70.89MM $472.43MM
Earnings Per Share** $-1.43 $-1.71 $-1.88

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.